NCT05693909View on ClinicalTrials.gov

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

October 31, 2027

Study Completion Date

May 31, 2028

Conditions
Beta Thalassemia Major AnemiaMyelodysplastic Syndrome
Interventions
DRUG

SP-420

Capsules for oral intake

Trial Locations (1)

Unknown

RECRUITING

Pharmacosmos Investigational Site, Copenhagen

Sponsors

Lead Sponsor

Pharmacosmos A/S

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Pharmacosmos A/S

INDUSTRY